| Scorecard |
|---|
|
3 / 5 Stars
|
|
Lipper
2
3
5
4
2
|
|
Zacks Investment Research
3
(Hold)
|
|
Standard & Poor's
4 / 5 Stars
|
|
TheStreet.com
A+
(Buy)
|
Fund Holdings
Asset Allocation
| % Long | % Net | |
|---|---|---|
| Cash | 0.02 | 0.02 |
| Stocks | 86.21 | 86.21 |
| Bonds | 0.0 | 0.0 |
| Other | 0.0 | 0.0 |
| Foreign Bonds | 3.7 | 3.7 |
| Foreign Stocks | 10.07 | 10.07 |
| Convertible | 0.0 | 0.0 |
| Preferred | 0.0 | 0.0 |
Updated 04.30.2013
Top 10 Holdings
Performance as of 05.31.2013
Portfolio as of 04.30.2013
| Ticker | YTD Return % | % Net Assets | |
|---|---|---|---|
| Pfizer Inc | PFE | 12.56 | 4.23 |
| Gilead Sciences Inc | GILD | 44.64 | 4.18 |
| Merck & Co Inc | MRK | 19.39 | 4.11 |
| Johnson & Johnson | JNJ | 22.65 | 3.92 |
| Central Cash Management Fd Central Cash Management Fd | --- | --- | 3.7 |
| Amgen Inc | AMGN | 16.09 | 3.23 |
| Celgene Corporation | CELG | 54.06 | 2.8 |
| Eli Lilly and Company | LLY | 9.73 | 2.66 |
| UnitedHealth Group Inc | UNH | 16.17 | 2.33 |
| Bristol-Myers Squibb Company | BMY | 48.17 | 2.2 |
